tetano
Editor, Senior Moderator
Diseases
. 2021 Apr 19;9(2):32.
doi: 10.3390/diseases9020032.
SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis
Amado Diaz de la Fe[SUP] 1 [/SUP], Alejandro Armando Pel?ez Su?rez[SUP] 1 [/SUP], Marinet Fuentes Campos[SUP] 2 [/SUP], Maivis Noem? Cabrera Hern?ndez[SUP] 3 [/SUP], Carlos-Alberto Goncalves[SUP] 4 [/SUP], Stephen Schultz[SUP] 5 [/SUP], Dario Siniscalco[SUP] 6 [/SUP], Maria Angeles Robinson-Agramonte[SUP] 7 [/SUP]
Affiliations
Abstract
The novel coronavirus can cause a severe respiratory disease with impact on the central nervous system, as has been reported by several medical health services. In the COVID-19 pandemic caused by the SARS-CoV-2 neurotrophic virus, neurologists have focused their attention on the early identification of suggestive manifestations of the neurological impact of the disease. In this context, they are exploring related chronic disease and the possibility of achieving a more effective understanding of symptoms derived from COVID-19 infection and those derived from the course of preexisting neurological disease. The present review summarizes evidence from the infection with SARS-CoV-2 and the management of the risks of multiple sclerosis and how it is related to the risks of general comorbidities associated with COVID-19. In addition, we reviewed other factors characteristic of MS, such as relapses, and the maximum tolerated dose of treatment medications from clinical and experimental evidence.
Keywords: COVID-19; SARS-CoV-2; benefit versus risk in multiple sclerosis (BRMS); multiple sclerosis (MS).
. 2021 Apr 19;9(2):32.
doi: 10.3390/diseases9020032.
SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis
Amado Diaz de la Fe[SUP] 1 [/SUP], Alejandro Armando Pel?ez Su?rez[SUP] 1 [/SUP], Marinet Fuentes Campos[SUP] 2 [/SUP], Maivis Noem? Cabrera Hern?ndez[SUP] 3 [/SUP], Carlos-Alberto Goncalves[SUP] 4 [/SUP], Stephen Schultz[SUP] 5 [/SUP], Dario Siniscalco[SUP] 6 [/SUP], Maria Angeles Robinson-Agramonte[SUP] 7 [/SUP]
Affiliations
- PMID: 33921878
- DOI: 10.3390/diseases9020032
Abstract
The novel coronavirus can cause a severe respiratory disease with impact on the central nervous system, as has been reported by several medical health services. In the COVID-19 pandemic caused by the SARS-CoV-2 neurotrophic virus, neurologists have focused their attention on the early identification of suggestive manifestations of the neurological impact of the disease. In this context, they are exploring related chronic disease and the possibility of achieving a more effective understanding of symptoms derived from COVID-19 infection and those derived from the course of preexisting neurological disease. The present review summarizes evidence from the infection with SARS-CoV-2 and the management of the risks of multiple sclerosis and how it is related to the risks of general comorbidities associated with COVID-19. In addition, we reviewed other factors characteristic of MS, such as relapses, and the maximum tolerated dose of treatment medications from clinical and experimental evidence.
Keywords: COVID-19; SARS-CoV-2; benefit versus risk in multiple sclerosis (BRMS); multiple sclerosis (MS).